Investors

MEDIAN Technologies strengthens IP portfolio with US patent

10 September 2015, Sophia Antipolis, France

Notice of Allowance of the United States Patent and Trademark Office (USPTO) for patent application covering a set of image processing algorithms developed by MEDIAN Technologies.

MEDIAN Technologies (ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announces that it has strengthened its IP portfolio following the United States Patent and Trademark Office’s (USPTO) Notice of Allowance related to the patent US 9092691 B1.

The patent application covers a set of computing systems and methods to automatically extract biomarkers from medical images. Those imaging biomarkers will allow physicians to identify and classify pathologies for most cancers; they also will allow physicians to determine which patients are more likely to respond to a specific therapy and to evaluate assess their response to therapy.

Imaging biomarkers have a tremendous potential in the evaluation of response to therapy of cancer patients. By providing highly reliable indexes of therapy efficacy, imaging biomarkers are key to evaluate cytotoxic or non-cytotoxic drugs during clinical trials, and to diagnose and follow patients in clinical routine.

This patent further strengthens our intellectual property around our Lesion Management Solution (LMS) technology. It covers methods to compute imaging biomarkers from standard imaging techniques, such as CT scanner and MRI. Those imaging techniques are widely available in hospital imaging departments, used in clinical routine and completely non-invasive, said Fredrik Brag, CEO of MEDIAN Technologies. “Moreover, we are proud to continue our Research and Development activities within the field of advanced imaging biomarkers, as they are essential for the development of personalized medicine in oncology and in other therapeutic areas”

About Median Technologies.

Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.

Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.

Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.

“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”

Contacts

MEDIAN Technologies

Fredrik Brag
CEO
+33 4 92 90 65 82
fredrik.brag@mediantechnologies.com

Actifin (Investors)

Ghislaine Gasparetto
+33 1 56 88 11 11
ggasparetto@actifin.fr

Alizé RP (Press)

Caroline Carmagnol
Wendy Rigal

+33 1 44 54 36 66
median@alizerp.com

Cookies help us deliver our services. By using our services, you agree to our use of cookies.